Company says it has isolated virus strains for research

Shenzhen Kangtai Biological Products Co has successfully isolated multiple strains of the Delta variant of the coronavirus in a step that could lead to improved vaccines, media reported on Wednesday.
The report by Shenzhen Special Zone Daily quoted a company executive as saying quality requirements for human vaccines will be strictly followed in the evaluation of the isolated strains.
"In response to new challenges in global epidemic prevention and control, Kangtai will fully promote the R&D and industrialization of the vaccine against the coronavirus variant," the executive said, adding that the inactivated COVID-19 vaccine developed by the company and approved for emergency use in China, is still protective and produces a good immune response to a variety of coronavirus variants.
- A guardian of Tibetan Buddhism grottoes in remote western Xizang
- C909 marks 9 years in commercial service
- Securing the harvest: China bets on high-tech seeds and tech-driven farming
- Simplified maternity allowance to boost more birth-friendly China quest
- Cambodian princess explores the art of calligraphy in Linyi
- Ammonia-fueled vessel 'Anhui' completes maiden voyage